A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer

European Journal of Human Genetics

Volumn 11, Issue 12, 2003, Pages 955-958

  Jakubowska, Anna ^a   Scott, Rodney ^b   Menkiszak, Janusz ^a   Gronwald, Jacek ^a   Byrski, Tomasz ^a   Huzarski, Tomasz ^a   Górski, Bohdan ^a   Cybulski, Cezary ^a   Dȩbniak, Tadeusz ^a   Kowalska, Elzbieta ^a   Starzyńska, Teresa ^a   Ławniczak, Małgorzata ^a   Narod, Steven ^c   Lubinski, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Centre for Research on Women's Health   (Canada)

Author keywords

BRCA2 gene; Mutation; Ovarian cancer; Stomach cancer

Indexed keywords

BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENVIRONMENTAL IMPACT; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; GERM LINE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; OVARY CANCER; POLAND; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; STOMACH CANCER;

BREAST NEOPLASMS; FEMALE; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; POLAND;

FALLOPIA;

EID: 0346656816     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201064     Document Type: Article

References (25)

1. Ford D, Easton DF, Stratton M et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-689.
2. BCLC - The Breast Cancer Linkage Consortium: Cancer risk in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316.
3. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H: Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999; 35: 1248-1257.
4. Jakubowska A, Nej K, Huzarski T, Scott R, Lubiñski J: BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002; 87: 888-891.
5. Risch HA, McLaughlin JR, Cole DE et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-710.
6. Moslehi R, Chu W, Karlan B et al: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66: 1259-1272.
7. 2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 1993; 31: 321-328.
8. Gorski B, Byrski T, Huzarski T et al: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000; 66: 1963-1968.
9. Gershoni-Baruch R, Dagan E, Fried G et al: Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer 2000; 36: 983-986.
10. Foulkes WD, Brunet JS, Warner E et al: The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet 1999; 65: 1776-1779.
11. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early onset breast cancer. J Nutl Cancer Inst 2001; 93: 1215-1223.
12. Ikeda N, Miyoshi Y, Yoneda K et al: Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 2001; 91: 83-88.
13. Vehmanen P, Friedman LS, Eerola H et al: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997; 6: 2309-2315.
14. Meindl A: German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002; 97: 472-480.
15. Grzybowska E, Zientek H, Jasinska A et al: High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum Mutat 2000; 16: 482-490.
16. van Der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E: Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutat 2000; 15: 480-481.
17. Fodor FH, Weston A, Bleiweiss IJ et al: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63: 45-51.
18. Warner E, Foulkes W, Goodwin P et al: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999; 91: 1241-1247.
19. Figer A, Irmin L, Geva R et al: The rate of the 6174delT mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer 2001; 84: 478-481.
20. Johannesdottir G, Gudmundsson J, Bergthorsson JT et al: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996; 56: 3663-3665.
21. Thorlacius S, Stuewing JP, Hartge P et al: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352: 1337-1339.
22. Thorlacius S, Sigurdsson S, Bjarnadottir H et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997; 60: 1079-1084.
23. Tulinius H, Olafsdottir GH, Sigvaldason H et al: The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 2002; 39: 457-462.
24. Thompson D, Easton D: Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-419.
25. Gayther SA, Mangion J, Russell P et al: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15: 103-105.